ASBP Aspire Biopharma Holdings, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ASBP matters now
Aspire Biopharma Holdings, Inc. (ASBP) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.01 with -0.99% on the session and $693.4K in market capitalization; recent performance reads 1-month +12.86% and YTD -95.85%.
The latest financial table shown here is Q1 2026, with revenue of $28.4K, net income of $-3.2M, and EPS of $-2.16. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -818.1%.
The latest indexable market news headline is "Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs" from Accesswire.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.54
P/S
21.97
EV/EBITDA
-1.07
DCF Value
$-0.53
FCF Yield
-818.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
16.3%
Operating Margin
-15745.9%
Net Margin
-34039.7%
ROE
199.4%
ROA
-165.3%
ROIC
-121.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $28.4K | $-3.2M | $-2.16 |
| Q4 2025 | $4.3K | $-4.7M | $-3.15 |
| FY 2025 | $6.2K | $-24.5M | $-16.38 |
| Q3 2025 | $1.9K | $-1.9M | $-1.49 |
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.16
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.